Business
Medicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the 5th Annual International Cancer Immunotherapy Conference
Medicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the 5th Annual International Cancer Immunotherapy Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Sept. 30, 2019\n\n\n\nResults show superiority and desired differentiation from competing IL-2 programs\n TORONTO, Sept. 30, 2019 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company developing first-in-class Superkines and Empowered Cytokines, announces the presentation of new pre-clinical data from its IL-2 Superkine program. The data was presented as a poster entitled \"Long-acting MDNA109: Emerging IL-2 Superkines displaying potent anti-tumoral responses\" this past weekend on September 27th, 2019 at the International Cancer Immunotherapy Conference held in Paris, France. \nThe presentation by Dr. Minh To, Director of Pre-clinical Development at Medicenna, reported additional preclinical data to support the differentiating characteristics of long-acting MDNA109 variants and their potency in vitro and in vivo from other long-acting IL2 programs.  \n\"In preclinical studies, we have combined MDNA109 variants with checkpoint inhibitors and we see very dramatic cure rates in mice,\" states Dr. Minh To. \"In addition, when you re-challenge these mice on the opposite flank with more tumor, these tumors simply don't grow, showing long-term protection against tumor development and prevention of relapse.\" \n\"We have an exciting pre-clinical program being built around the IL-2 Superkine platform, where we just announced our lead clinical candidate, MDNA19,\" states Rosemina Merchant, Chief Development Officer of Medicenna. \"By engineering a potent CD122 directed Superkine with a superior safety and PK profile, we believe that MDNA19 could emerge as a best-in-class IL-2 with its unique ability to preferentially stimulate cancer killing T cells as reported by an independent study published last month in Nature Communi...